PIKing the right patient

Clin Cancer Res. 2010 Jul 15;16(14):3523-5. doi: 10.1158/1078-0432.CCR-10-1201. Epub 2010 Jun 10.

Abstract

HER2 amplification and PIK3CA mutation were validated as biomarkers for sensitivity to the single-agent phosphoinositide 3-kinase (PI3K) inhibitor, GDC-0941, in breast cancer models. A novel expression profile was developed to identify other breast cancers sensitive to PI3K inhibitors. These expression studies highlighted feedback networks connecting TORC1, PI3K, and mitogen-activated protein kinase (MAPK) pathways, and underscored the potential for combination therapies.

Publication types

  • Comment

MeSH terms

  • Animals
  • Biomarkers, Tumor / antagonists & inhibitors
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism
  • Disease Models, Animal
  • Female
  • Gene Expression Profiling
  • Humans
  • Indazoles / pharmacology*
  • Mice
  • Mitogen-Activated Protein Kinases / metabolism
  • Mutation
  • Phosphatidylinositol 3-Kinase / genetics
  • Phosphatidylinositol 3-Kinase / metabolism
  • Phosphoinositide-3 Kinase Inhibitors*
  • Receptor, ErbB-2 / metabolism
  • Sulfonamides / pharmacology*
  • Transcription Factors / metabolism

Substances

  • 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
  • Biomarkers, Tumor
  • CRTC1 protein, human
  • Indazoles
  • Phosphoinositide-3 Kinase Inhibitors
  • Sulfonamides
  • Transcription Factors
  • Phosphatidylinositol 3-Kinase
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Mitogen-Activated Protein Kinases